Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin

John C. Reed, Lynn Meister, Shigeki Tanaka, Michael Cuddy, Samuel Yum, Claudia Geyer, David E Pleasure

Research output: Contribution to journalArticle

228 Citations (Scopus)

Abstract

The bcl2 protooncogene was originally discovered because of its involvement in t(14;18) chromosomal translocations frequently found in non-Hodgkin's lymphomas. The expression of this gene is reported to be highly tissue specific, with bcl2 mRNAs being readily detectable only in hematolymphoid tissues and brain. To explore the possible involvement of bcl2 in neural tumors, we surveyed a variety of tumor cell lines for the presence of the p26-BCL2 protein by immunoprecipitation and immunoblotting methods. Very high levels of BCL2 protein were found in three of nine neuroblastoma (NB) cell lines examined; these levels of p26-BCL2 were comparable to lymphoma cell lines that contain a t(14;18). Despite the impressive relative amounts of BCL2 protein, however, no structural alterations or changes in the methylation status of bcl2 genes were detected in these NB cell lines by conventional Southern blotting. Of the other NB cell lines surveyed, three contained intermediate levels of BCL2 and another three cell lines had little or no detectable BCL2 protein, raising the possibility that determination of relative levels of BCL2 protein may help to segregate neuroblastomas into groups with different biological and clinical characteristics. BCL2 protein levels were not influenced by induction of neuronal differentiation with nerve growth factor in two of the two cell lines examined [SH-SY5Y (high BCL2); GICAN (low BCL2)] and did not correlate with N-MYC gene amplification or expression of nerve growth factor receptors. NB cell lines that contained little or no detectable BCL2 protein, however, tended to contain significant proportions of flat epithelioid cells, whereas bcl2-expressing cell lines were composed primarily of neuronal-like cells, suggesting that expression of this protooncogene correlates with the differentiation characteristics of these tumor cell lines. In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas. With regard to tumors of central nervous system origin, bcl2 expression was absent from most medulloblastomas but was detected at moderate to low levels in a retinoblastoma and some glioblastoma multiforme cell lines. Taken together, these findings imply that bcl2 protooncogene expression is differentially regulated within the various lineages of cells that give rise to the nervous system.

Original languageEnglish (US)
Pages (from-to)6529-6538
Number of pages10
JournalCancer Research
Volume51
Issue number24
StatePublished - Dec 15 1991
Externally publishedYes

Fingerprint

Proto-Oncogene Proteins c-bcl-2
Tumor Cell Line
Neuroblastoma
Cell Line
Nerve Growth Factor Receptors
Gene Expression
Neurofibroma
Central Nervous System Neoplasms
Epithelioid Cells
Genetic Translocation
Medulloblastoma
Ewing's Sarcoma
Retinoblastoma
Gene Amplification
Nerve Growth Factor
Glioblastoma
Southern Blotting
Immunoprecipitation
Immunoblotting
Non-Hodgkin's Lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Reed, J. C., Meister, L., Tanaka, S., Cuddy, M., Yum, S., Geyer, C., & Pleasure, D. E. (1991). Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Research, 51(24), 6529-6538.

Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. / Reed, John C.; Meister, Lynn; Tanaka, Shigeki; Cuddy, Michael; Yum, Samuel; Geyer, Claudia; Pleasure, David E.

In: Cancer Research, Vol. 51, No. 24, 15.12.1991, p. 6529-6538.

Research output: Contribution to journalArticle

Reed, JC, Meister, L, Tanaka, S, Cuddy, M, Yum, S, Geyer, C & Pleasure, DE 1991, 'Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin', Cancer Research, vol. 51, no. 24, pp. 6529-6538.
Reed JC, Meister L, Tanaka S, Cuddy M, Yum S, Geyer C et al. Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. Cancer Research. 1991 Dec 15;51(24):6529-6538.
Reed, John C. ; Meister, Lynn ; Tanaka, Shigeki ; Cuddy, Michael ; Yum, Samuel ; Geyer, Claudia ; Pleasure, David E. / Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin. In: Cancer Research. 1991 ; Vol. 51, No. 24. pp. 6529-6538.
@article{fc64f342223d448c92cfb9fb8ebc2569,
title = "Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin",
abstract = "The bcl2 protooncogene was originally discovered because of its involvement in t(14;18) chromosomal translocations frequently found in non-Hodgkin's lymphomas. The expression of this gene is reported to be highly tissue specific, with bcl2 mRNAs being readily detectable only in hematolymphoid tissues and brain. To explore the possible involvement of bcl2 in neural tumors, we surveyed a variety of tumor cell lines for the presence of the p26-BCL2 protein by immunoprecipitation and immunoblotting methods. Very high levels of BCL2 protein were found in three of nine neuroblastoma (NB) cell lines examined; these levels of p26-BCL2 were comparable to lymphoma cell lines that contain a t(14;18). Despite the impressive relative amounts of BCL2 protein, however, no structural alterations or changes in the methylation status of bcl2 genes were detected in these NB cell lines by conventional Southern blotting. Of the other NB cell lines surveyed, three contained intermediate levels of BCL2 and another three cell lines had little or no detectable BCL2 protein, raising the possibility that determination of relative levels of BCL2 protein may help to segregate neuroblastomas into groups with different biological and clinical characteristics. BCL2 protein levels were not influenced by induction of neuronal differentiation with nerve growth factor in two of the two cell lines examined [SH-SY5Y (high BCL2); GICAN (low BCL2)] and did not correlate with N-MYC gene amplification or expression of nerve growth factor receptors. NB cell lines that contained little or no detectable BCL2 protein, however, tended to contain significant proportions of flat epithelioid cells, whereas bcl2-expressing cell lines were composed primarily of neuronal-like cells, suggesting that expression of this protooncogene correlates with the differentiation characteristics of these tumor cell lines. In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas. With regard to tumors of central nervous system origin, bcl2 expression was absent from most medulloblastomas but was detected at moderate to low levels in a retinoblastoma and some glioblastoma multiforme cell lines. Taken together, these findings imply that bcl2 protooncogene expression is differentially regulated within the various lineages of cells that give rise to the nervous system.",
author = "Reed, {John C.} and Lynn Meister and Shigeki Tanaka and Michael Cuddy and Samuel Yum and Claudia Geyer and Pleasure, {David E}",
year = "1991",
month = "12",
day = "15",
language = "English (US)",
volume = "51",
pages = "6529--6538",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin

AU - Reed, John C.

AU - Meister, Lynn

AU - Tanaka, Shigeki

AU - Cuddy, Michael

AU - Yum, Samuel

AU - Geyer, Claudia

AU - Pleasure, David E

PY - 1991/12/15

Y1 - 1991/12/15

N2 - The bcl2 protooncogene was originally discovered because of its involvement in t(14;18) chromosomal translocations frequently found in non-Hodgkin's lymphomas. The expression of this gene is reported to be highly tissue specific, with bcl2 mRNAs being readily detectable only in hematolymphoid tissues and brain. To explore the possible involvement of bcl2 in neural tumors, we surveyed a variety of tumor cell lines for the presence of the p26-BCL2 protein by immunoprecipitation and immunoblotting methods. Very high levels of BCL2 protein were found in three of nine neuroblastoma (NB) cell lines examined; these levels of p26-BCL2 were comparable to lymphoma cell lines that contain a t(14;18). Despite the impressive relative amounts of BCL2 protein, however, no structural alterations or changes in the methylation status of bcl2 genes were detected in these NB cell lines by conventional Southern blotting. Of the other NB cell lines surveyed, three contained intermediate levels of BCL2 and another three cell lines had little or no detectable BCL2 protein, raising the possibility that determination of relative levels of BCL2 protein may help to segregate neuroblastomas into groups with different biological and clinical characteristics. BCL2 protein levels were not influenced by induction of neuronal differentiation with nerve growth factor in two of the two cell lines examined [SH-SY5Y (high BCL2); GICAN (low BCL2)] and did not correlate with N-MYC gene amplification or expression of nerve growth factor receptors. NB cell lines that contained little or no detectable BCL2 protein, however, tended to contain significant proportions of flat epithelioid cells, whereas bcl2-expressing cell lines were composed primarily of neuronal-like cells, suggesting that expression of this protooncogene correlates with the differentiation characteristics of these tumor cell lines. In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas. With regard to tumors of central nervous system origin, bcl2 expression was absent from most medulloblastomas but was detected at moderate to low levels in a retinoblastoma and some glioblastoma multiforme cell lines. Taken together, these findings imply that bcl2 protooncogene expression is differentially regulated within the various lineages of cells that give rise to the nervous system.

AB - The bcl2 protooncogene was originally discovered because of its involvement in t(14;18) chromosomal translocations frequently found in non-Hodgkin's lymphomas. The expression of this gene is reported to be highly tissue specific, with bcl2 mRNAs being readily detectable only in hematolymphoid tissues and brain. To explore the possible involvement of bcl2 in neural tumors, we surveyed a variety of tumor cell lines for the presence of the p26-BCL2 protein by immunoprecipitation and immunoblotting methods. Very high levels of BCL2 protein were found in three of nine neuroblastoma (NB) cell lines examined; these levels of p26-BCL2 were comparable to lymphoma cell lines that contain a t(14;18). Despite the impressive relative amounts of BCL2 protein, however, no structural alterations or changes in the methylation status of bcl2 genes were detected in these NB cell lines by conventional Southern blotting. Of the other NB cell lines surveyed, three contained intermediate levels of BCL2 and another three cell lines had little or no detectable BCL2 protein, raising the possibility that determination of relative levels of BCL2 protein may help to segregate neuroblastomas into groups with different biological and clinical characteristics. BCL2 protein levels were not influenced by induction of neuronal differentiation with nerve growth factor in two of the two cell lines examined [SH-SY5Y (high BCL2); GICAN (low BCL2)] and did not correlate with N-MYC gene amplification or expression of nerve growth factor receptors. NB cell lines that contained little or no detectable BCL2 protein, however, tended to contain significant proportions of flat epithelioid cells, whereas bcl2-expressing cell lines were composed primarily of neuronal-like cells, suggesting that expression of this protooncogene correlates with the differentiation characteristics of these tumor cell lines. In addition to NBs, lower levels of BCL2 protein were also found in a variety of other neural crest-derived tumors and tumor cell lines, including some neuroepitheliomas, Ewing's sarcomas, neurofibromas, and melanomas. With regard to tumors of central nervous system origin, bcl2 expression was absent from most medulloblastomas but was detected at moderate to low levels in a retinoblastoma and some glioblastoma multiforme cell lines. Taken together, these findings imply that bcl2 protooncogene expression is differentially regulated within the various lineages of cells that give rise to the nervous system.

UR - http://www.scopus.com/inward/record.url?scp=0026346883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026346883&partnerID=8YFLogxK

M3 - Article

C2 - 1742726

AN - SCOPUS:0026346883

VL - 51

SP - 6529

EP - 6538

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 24

ER -